NEW YORK, Feb. 25, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that Mark Pruzanski, MD, President and Chief Executive Officer, will present a company overview at the Cowen and Company 33rd Annual Health Care Conference, being held at the Boston Marriott Copley Place in Boston, Massachusetts, on March 4, 2013 at 4:10-4:40 p.m. Eastern time.
The public may access Dr. Pruzanski's presentation live via webcast at http://wsw.com/webcast/cowen10/icpt/. A replay of the presentation will also be available and archived on Intercept's website for 2 weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA) is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to DSP. For more information about Intercept, please visit the Company's website at:www.interceptpharma.com.
For more information about Intercept, please contact Mark Pruzanski, M.D., or Barbara Duncan, both of Intercept Pharmaceuticals, at 1-646-747-1000.